Autofluorescence imaging colonoscopy for the diagnosis of dysplasia in ulcerative colitis.

T. Matsumoto,T. Moriyama,T. Yao,R. Mibu,M. Iida

DOI: https://doi.org/10.1002/IBD.20104

2007-05-01

Inflammatory Bowel Diseases

Abstract:

What problem does this paper attempt to address?

Efficacy of Ctla4-Ig in Preventing Acute Rejection of Fully Allogeneic Heart Allografts in Sensitized Recipients

J. Chen,J. Young,V. Vu,D. Ying,Q. Wang,A. Chong

DOI: https://doi.org/10.1097/00007890-201407151-01039

2014-01-01

Transplantation

Abstract:Belatacept, a high-affinity variant of CTLA4-Ig, is a recently approved immunosuppressive agent for the prevention of acute rejection. It functions as a potent antagonist of the CD28-B7 interactions, thereby inhibiting T cell co-stimulation and activation. Experimental data involving the transient use of CTLA4-Ig to induce allograft tolerance have shaped the current paradigm that CTLA-4Ig is ineffective at inhibiting memory T cell responses, and by extension T-dependent alloantibody responses. This resistance is explained by the acquisition of additional activation-induced costimulatory molecules by memory T cells. We noted that the efficacy of CTLA4-Ig as a continuously administered drug for controlling rejection in sensitized recipients has not been investigated. Here we report on the efficacy of CTLA4-Ig in preventing acute rejection in sensitized C57BL/6 recipients that had received BALB/c spleen cell transfusion 3-6 months previously. We set up four experimental groups. Group 1 (N=5): sensitized mice with HTX and CTLA4-Ig treated (Day -2, Day 0, Day2, then weekly (1 mg/dose) Group 2 (N=3): sensitized mice with HTX and no CTLA4-Ig, Group 3: (N=10) naive mice with HTX and CTLA4-Ig treated, Group 4 (N=10): naive mice with HTX and no CTLA4-Ig. In the untreated Groups 2 & 4, allografts were rejected within 7 days post-transplantation, whereas in Group 3 of naive mice receiving CTLA4-Ig, all the grafts survived long-term (>90 days). In Group 1 of sensitized recipients receiving CTLA4-Ig, the allografts survived for 42, 42, 49, >90, >90 days. The pre-transplant donor-specific antibody (DSA) titers in the recipients that went on to reject their graft was significantly higher compared to those that accepted their grafts. Furthermore, DSA titers increased post-transplantation in the recipients that went on to reject their allografts, whereas DSA titers decreased in those that accepted their grafts. In conclusion, these observations illustrate the efficacy of CTLA-4Ig treatment at controlling rejection in sensitized recipients, and underscore the barrier pre-transplantation DSA poses to long-term graft acceptance. This experimental model also provides a unique opportunity for testing if DSA promotes antibody-mediated rejection or alloreactive memory T cell priming and T cell-mediated rejection in CTLA4-Ig treated recipients, and for identifying therapies that promote long-term graft survival in sensitized recipients.
Precise Treatment of Acute Antibody-Mediated Cardiac Allograft Rejection in Rats Using C4d-targeted Microbubbles Loaded with Nitric Oxide

Tao Liao,Qiaojia Li,Yannan Zhang,Zhe Yang,Zhengyu Huang,Fei Han,Xiaolong Chen,Tinghui Yin,Jie Ren,Qiquan Sun

DOI: https://doi.org/10.1016/j.healun.2020.02.002

IF: 13.569

2020-01-01

The Journal of Heart and Lung Transplantation

Abstract:BACKGROUNDAntibody-mediated rejection (AMR) constitutes an important cause of cardiac allograft loss; however, all current therapeutic strategies represent systemic applications with unsatisfactory efficacy. Previously, we successfully non-invasively detected C4d, a specific marker for AMR diagnosis, in allografts using C4d-targeted microbubbles (MBC4d). In this study, we extended this approach by incorporating nitric oxide (NO), as high NO levels manifest immunosuppressive and anti-thrombotic effects.METHODSWe designed novel MBC4d loaded with NO (NO-MBC4d). A rat model of AMR was established by pre-sensitization with skin transplantation. Contrast-enhanced ultrasound (CEUS) images were obtained and quantitatively analyzed following NO-MBC4d injection. Allograft survival and histologic features were analyzed to evaluate the therapeutic effect and underlying mechanism of NO-MBC4d toward AMR.RESULTSWe successfully obtained CEUS images following NO-MBC4d injection and demonstrated that the ultrasound signal intensity of the myocardial area and clearance time of NO-MBC4d both increased with increased C4d grade, thereby realizing non-invasive diagnosis of AMR. Furthermore, allograft survival was significantly prolonged, and rejection was obviously attenuated following NO-MBC4d injection through significant suppression of thrombosis and reduction of inflammatory cell infiltrates. Overall, the therapeutic efficacy was significantly improved in the NO-MBC4d group compared with the control NO-MB group, demonstrating that precise treatment could significantly improve the therapeutic efficacy compared with that afforded by systemic applications.CONCLUSIONSThis study presented a novel tool to provide simultaneous non-invasive diagnosis and precise treatment of AMR using NO-MBC4d CEUS imaging, which may be expected to provide a better option for recipients with AMR in clinic.
A novel approach for HPLC determination of 2-cynaoacetamide using derivatization procedure with 2-hydroxyacetophenone as a new useful derivatization reagent.

Michal Douša,Jiří Břicháč,M. Tkadlecová,S. Man,J. Zezula,J. Hájíček,T. Pekárek

DOI: https://doi.org/10.1016/j.jpba.2016.06.016

IF: 3.571

2016-09-05

Journal of Pharmaceutical and Biomedical Analysis

Abstract:
Combination of cyclosporine A with donor bone marrow cell infusion prolongs heterotopic rat cardiac allograft survival time

Rui Jiang,Jiang-hua Cheng,Qiang He,Jian-yong Wu,Juan Jin

DOI: https://doi.org/10.3321/j.issn:1673-8225.2008.18.010

2008-01-01

Abstract:BACKGROUND: To avoid acute rejection,it is necessary to use imunosuppressive drug regimen for long term to control immune state.However,imunosuppressive drug regimen of allogenic organ transplantation increases infection incidence of recipients,and induction of allograft immunological tolerance might be an ideal method for solving these problems.The long-term immunologic tolerance has been able to be induced in the experimental rodent models.Among these protocols,donor bone marrow cell (DBMC) infusion exerts an important role in the induction of allograft immunological tolerance.OBJECTIVE: To investigate effects of combination of cyclosporine A (CsA) with DBMC infusion on heterotopic rat cardiac allograft survival time.DESIDN: A randomized controlled animal experiment.SETTING: Renal Disease Center,First Affiliated Hospital of Zhejing University School of Medicine.MATERIALS: This study was performed at the Laboratory Animal Center,Zhejiang University School of Medicine between March 2002 and December 2005.Inbred male Lewis rats (n=40,serving as donors) and male BN rats (n=60,serving as recipients) of SPF grade were used in this study.The protocol was approved by the Hospital's Ethic's Committee.METHODS: Forty rats prepared for heterotopic rat cardiac allograft were randomly divided into 4 groups,with 10 rats in each: control group,in which,rats received no treatment,CsA group,in which,rats received CsA infusion for 7 days successively; CsA +DBMC group,in which,rats received DBMCs during and 6 days after the surgery and additional 7 successive days of CsA infusion,and a DBMC group,in which,rats received DBMCs infusion during and 6 days after the surgery.In addition,BN rats that received beterotopic rat cardiac allograft served BN controls.The survival time of heteroropic rat cardiac allograft was investigated.Serum interleukin-2 level and tumor necrosis factor-α mRNA expression level in the transplanted cardiac allograft were measured. The percentage of antigen presenting cells (APC) from donor,CD3+CD25+ cells,CD4+CD25+ cells,CD86+ cells,and the ratio for CD4+CD45RC+ and CD4+CD45RC- in the recipient peripheral blood karyocytes were measured by flow cytometry 6,12 and 18 days after surgery.MAIN OUTCOME MEASURES: The survival time of beteruropic rat cardiac allograft,serum interleukin-2 (IL-2)level,tumor necrosis factor- α (TNF- α ) rnRNA expression level, rejection grading,the percentage of DBMCs in the recipient peripheral blood karyocytes,CD3+CD25+ cells,and CD4+CD25+ cells,as well as CD86 expression,and the ratio for CD4+CD45RC+ and CD4+CD45RC.RESULTS: Forty Lewis male rats and sixty male BN rats were all included in the final analysis. The heterotopic rat cardiac allograft survival time was longer in the CsA +DBMC group than in the control group and DBMC group (P ＜ 0.05). Serum IL-2 level and TNF- α mRNA expression were respectively lower in the CsA +DBMC group than in the control group and DBMC group ( P ＜ 0.05).The rejection was milder in the CsA +DBMC group than in the remaining 3 transplantation groups.In the CsA +DBMC group,CD 86 expression in the recipient peripheral blood karyocytes was markedly inhibited,and 6 and 12 days after surgery,the ratio for CD4+CD45RC+ and CD4+CD45RC- and the percentage of CD3+CD25+ were respectively lower compared to control group and DBMC group.DBMCs in the recipient peripheral blood karyocytes were more in rats that received DBMC infusion compared to rats that received no BDMC infusion.CONCLUSION: Short-term CsA treatment combined with DBMC infusion can lower acute rejection of heterotopic rat cardiac allograft and prolongs survival time of cardiac allograft.
Synergistic Effect of CsA and DBMC on Heterotopic Rat Cardiac Allograft Survival

姜睿,陈江华,何强,吴建永,金娟

DOI: https://doi.org/10.3760/cma.j.issn.0254-1785.2007.07.005

2007-01-01

Abstract:Objective To summarize the experience of long-term survival of the patients under- going orthotopic heart transplantation.Methods After male inbred Lewis(RT1~1)rat heart had been transplanted into the abdomen of male inbred BN(RT1~n)rat,the experimental rats were divided into 4 groups:group A served as control,receiving 1 ml saline infusion into the portal vein intra-operation for 7 days after heart transplantation;group B received cyclosporine(CsA)5 mg/(kg·day)for 7 days after surgery;group C treated with CsA(5 mg·kg~(-1)·d~(-1))combined with 1×10~8 DBMC infusion in- tra-transplantation and group D treated with 1×10~8 DBMC for 7 days after surgery.The survival time of donor hearts was observed.The level of serum 1L-2 was detected by enzyme-linked immunosorbent assay(ELISA)and the mRNA expression of TNF-αin the graft by RT-PCR on 6th day following the operation respectively.HE staining was used to examine all specimens of heart grafts on 6th day after operation.The number of CD3~+ CD25~+ cells,antigen presenting cells(APC)from donor,the ratio of CD4~+ CD45RC~+/CD4~+ CD45RC~- and CD86~+ ceils in the peripheral blood lymphocytes of receptors were measured by flow cytometry on day 6,12 and 18 after surgery.Results The mean graft survival time in the groups A,B,C and D was 7.2±0.4,15.2±2.3,21.6±3.2 and 7.8±0.8 days,respec- tively.There was significant difference in the ratio of CD4~+ CD45RC~+/CD4~+ CD45RC~-,the expres- sion of CD86 on the APC,the expression of TNF-αmRNA,the severity of acute graft rejection and serum IL-2 concentrations 6 days after surgery between group C and other groups(P0.05).The typical features of acute rejection were most marked in group A and the least in group C.CD4~+ CD25~+ cells had no significant changes in these groups.There was no significant difference in number of APC derived from donors between groups C and D at 18th day after surgery,but it was more than that in groups A and B(P0.05).Conclusion DBMC infusion after transplantation combined with short- term treatment with CsA can induce donor specific low-reactive action and prolong the allograft survi- val in rat cardiac transplantation.
Impact of Acute Rejection Episodes on Long-Term Renal Allograft Survival

Jy Wu,Jh Chen,Ym Wang,Jg Zhang,Z Zhu,Zf Shou,Sy Wang,P Zhang,Hf Huang,Q He

IF: 6.133

2003-01-01

Chinese Medical Journal

Abstract:OBJECTIVETo assess the impact of the number, and time of acute rejection (AR) and outcome of anti-rejection therapy on the long-term survival of renal allografts and the relative risk factors.METHODSThe Kaplan-Meier analysis and log-rank test were used to calculate the survival rates of patients and grafts in no acute rejection group (NAR, 895 patients), 1 rejection episode group (1AR, 183), 2 and more than 2 rejection episodes group (2AR, 17), acute rejection group [AR (1AR + 2AR), 200], early acute rejection group (within 90 days after transplantation, EAR, 125), late acute rejection group (91 days later, LAR, 58), completely AR reversed group (CAR, 105), and incompletely AR reversed group (IAR, 68). The relative risk factors were analyzed by the Cox proportional hazards regression.RESULTSThe 5- and 10-year survival rates of renal allografts were 75.4% and 17.1% in AR and 93.2% and 86.5% in the NAR group (P < 0.0001). The long-term graft survival was much lower in the 2AR group than in the NAR or 1AR groups (P < 0.0001 and P = 0.002, respectively). It was similar in either the NAR or CAR groups (P = 0.31), but it was significantly lower (P < 0.0001) in the IAR group. Multivariate Cox regression analysis revealed that the outcome of anti-rejection therapy is an important risk factor affecting the long-term survival of allografts.CONCLUSIONSAR is significantly associated with poor long-term survival of renal allografts. But the long-term graft survival of patients with one acute rejection but completely reversed is not significantly different from that of patients without acute rejection.
Effect of acute humoral rejection on renal allograft survival

Ren-ding WANG,Hui-ping WANG,Jian-yong WU,Yi-min WANG,Jian-guo ZHANG,Hong-feng HUANG,Qiang HE,Jiang-hua CHEN

DOI: https://doi.org/10.3760/cma.j.issn.0254-1785.2010.06.005

2010-01-01

Abstract:Objective To explore the effect of acute humoral rejection on kidney graft survival.Methods 1098 patients received cadaveric renal transplant from January 2002 to December 2008 in our center. All patients were given triple immunosuppressants including tacrolimus or cyclosporine.According to patients who experienced biopsy-proved humoral rejection and cellular rejection within one year post-transplant, there were 53 cases in humoral rejection group, 109 in cellular rejection group (including 63 patients with borderline change), and 936 in normal group. Patients who experienced acute rejection received mythyl-prednisolone pulse, or received anti-CD3 antibody/plasma exchange/globulin. Clinical characteristics before operation including sex, age, HLA mismatch, panel reactive antibody, cold/warm ischemic time, graft loss rate and graft survival were compared among three groups. The effect of completely reversed cellular rejection and humoral rejection on graft survival was analyzed. Results There was no significant difference in sex, age and cold ischemic time among three groups, but there was significant difference in warm ischemic time, level of PRA and HLA mismatch between cellular rejection group or humor rejection group and normal group (P＜0. 05). During a follow-up period, the incidence of graft loss in humoral rejection group was 27.4 %, significantly higher than 7.3 % in cellular rejection group and 2.2 % in normal group, P＜0. 001. Kaplan-Meier analysis revealed the survival rate of grafts in humoral rejection group was significantly lower than in cellular rejection group and normal group (P＜0.001 ). After patients with irreversible rejection were excluded,there was no significant difference in the survival rate of grafts among the three groups.Conclusion Patients with acute humoral rejection survived with inferior graft outcome,but completely reversible rejection showed no effect on the graft survival.
Effect of β-Nicotinamide Adenine Dinucleotide on Acute Allograft Rejection After Rat Lung Transplantation

Jonas P Ehrsam,Jin Chen,Martina Haberecker,Stephan Arni,Ilhan Inci

DOI: https://doi.org/10.1097/TXD.0000000000001516

2023-08-09

Abstract:Acute rejection is still a major limitation for a successful outcome in lung transplantation. Since β-nicotinamide adenine dinucleotide (NAD+) has been shown to have various immunomodulatory properties on the innate and adaptive immune system, we evaluate here a potential protective effect of NAD+ against acute lung rejection. Methods: Rat single-lung transplantation was performed in 2 groups (n = 8 per group), using Brown-Norway donors and major histocompatibility complex-mismatched Lewis recipients. Recipients of the NAD+ group received 1000 mg/kg NAD+ intraperitoneally before transplantation and daily thereafter until euthanasia, whereas the control group received saline solution. At autopsy on day 5, blood samples were analyzed and the lung allograft was assessed by bronchioalveolar lavage, histology, and immunochemistry. Results: The NAD+ group maintained an intact compliant lung tissue, a strong trend of lower acute cellular rejection (A3 versus A3-A4) and significantly less lymphocytic bronchiolitis (B0-B2R versus B1R-Bx). In addition, a trend of fewer alveolar CD68+ macrophages and significantly fewer interstitial CD163+ macrophages was observed. Bronchoalveolar lavage in the NAD+ group showed significantly fewer proinflammatory cytokines interleukin (IL)-6, IL-13, TNFα, and a protective IL-6/IL-10-ratio. In blood samples, we observed significantly fewer neutrophils, and proinflammatory GRO/KC in the NAD+ group. Conclusions: NAD+ might be a promising substance in prevention of acute allograft rejection in lung transplantation.
[Completely Reversed Acute Rejection Episodes Do Not Influence the Long-Term Renal Allograft Survival].

Jian-yong Wu,Jiang-hua Chen,Yi-min Wang,Jian-guo Zhang,Cong Zhu,Su-ya Wang,Ping Zhang,Hong-feng Huang,Qiang He

DOI: https://doi.org/10.3760/j:issn:0376-2491.2003.02.006

2003-01-01

Abstract:OBJECTIVE:To assess the influence of times and duration of acute rejection episodes and the effect of antirejection therapy in renal transplantation recipients on the long-term survival of renal allograft.METHODS:The clinical data of 946 patients who received renal transplantation were analyzed to analyze the survival of renal allograts in different conditions: times of rejection episode, time of onset of acute rejection, and effect of antirejection therapy by life table and Wilcoxon test, and to identify the risk factors through Cox regression analysis.RESULTS:During the follow-up with a range of 3 approximately 158 months acute rejection occurred in 172 patients. The 946 cases of kidney transplantation were divided into rejection free group (NAR, n = 774), one time rejection group (1AR, n = 159), and twice and more rejection group (2AR, n = 13) according to the times of rejection. The 1AR group was subdivided into completely reversed group (CAR) and incompletely reversed group (1AR). The 1AR cases were subdivided into early-stage rejection group (EAR, with episode within 90 days after transplantation, n = 112) and late-stage rejection group (LAR, with episode 90 days later transplantation, n = 47) according to the onset time of rejection episode. The five-year survival rate was 70.9% in the AR group (n = 172) and was 93.3% in the NAR group (P < 0.000 1). The ten-year survival rate of renal allografts was 29.8% in the AR group, and was 83.3% in the NAR group (P < 0.000 1). The 5-year survival rate of renal allograft was less than 30% in the 2AR group, significantly lower than those in the NAR and IAR groups (P < 0.000 1 and P< 0.003). The 5-year survival rate of renal allograft was 89.0% in the EAR group, significantly higher than that in the LAR group (48.9%, P < 0.000 1). The 8-year survival rate was 84.3% in the EAR group, significantly higher than that in the LAR group (32.1%, P < 0.000 1). Both the survival rates of renal allograft in the EAR and LAR groups were significantly lower than that in the NAR group (P = 0.025 and P < 0.000 1). The condition had been completely reversed in 95 patients and incompletely reversed in 54 patients, and failed to be improved in 10 patients out of the 159 cases in the IAR group after antirejection therapy. The 5-year survival rate of renal allograft was 93.9% in the CAR group, significantly higher than that in the IAR group (63.1%, P < 0.000 1) but not significantly different from that in the NAR group (P = 0.96). The 8-year survival rate of renal allograft was 89.2% in the CAR group, significantly higher than that in the IAR group (41.4%, P < 0.000 1) but not significantly different from that in the NAR group (P = 0.96). The time of rejection onset was not the main factor effecting survival rate of grafts. The main risk factor influencing the long-term survival of renal allograft was the therapeutic effect after the onset of rejection with a risk rate of 3.14.CONCLUSION:The acutely rejected renal allografts have poor long-term survival. The long-term survival rate of renal allograts with acute rejection that occurs only once and is completely recovered after antirejection therapy is not significantly different from that of the renal allografts in NAR group.
Inactivation Of T-Cell Receptor-Mediated Integrin Activation Prolongs Allograft Survival In Amap-Deficient Mice

Jiong Tian,Oliver Pabst,Dorothee Roemermann,Susanne Skubich,Reinhold Foerster,Jan Beckmann,Jiang-Hua Chen,Matthias W. Hoffmann

DOI: https://doi.org/10.1097/01.tp.0000269724.06142.92

2007-01-01

Transplantation

Abstract:Background. Signaling through the T cell receptor (TCR) leads to profound changes in the function and properties of T cells, including integrin activation. Adhesion and degranulation promoting adapter protein (ADAP) is an adapter protein linking T cell receptor stimulation to integrin activation. We aim to clarify how disruption of TCR-mediated integrin activation affects alloreactive immune responses.Methods. In vitro T cell proliferation and the cytokine production was determined. In vivo cytotoxic T lymphocyte (CTL) activity was measured as well. Allogenic skin and heart transplantation was used to test the in vivo role of ADAP in alloimmune responses. Histology and flow cytometry was applied to analyze the graft infiltrating lymphocytes.Results. Upon stimulation with allogenic dendritic cells ADAP-deficient T cells displayed impaired proliferative responses compared to wild type (WT) T cells. This was accompanied by significantly decreased production of the cytokine interleukin-2. In contrast, the in vivo CTL activity in ADAP-deficient mice was comparable to that of WT mice. Consistently, we observed a prolongation of fully major histocompatibility complex (MHC)-mismatched heart transplants in ADAP deficient mice. Protection of allogenic heart grafts in ADAP-deficient mice was accompanied by a decrease in the infiltration, proliferation and activation of T cells in the allograft. However, no effect was observed after fully MHC-mismatched skin transplantation.Conclusions. We have shown that although ADAP is dispensable for the rejection of allografts, ADAP function plays an important role for the efficacy of graft rejection. ADAP's main function appears to affect the induction phase of the immune response.
Histological Isolated Endarteritis Benefits Glomerular Filtration Rate And Allograft Survival After Anti-Rejection Treatment

Rending Wang,Jinwen Lin,Yan Jiang,Zhimin Chen,Jianyong Wu,Jianghua Chen

2019-01-01

Abstract:Isolate endarteritis after renal transplantation has been regarded as T cell-mediated acute rejection in Banff classification. Recently, results from DNA microarrays suggested that isolate endarteritis did not represent T cell-mediated acute rejection exactly and its effect on allograft outcomes was unclear. A total 192 cases of biopsy-proved acute cellular rejection had been recorded between September 2001 to December 2014. There were 111 cases in endarteritis negative group and 81 cases in endarteritis positive group. The baseline information, serum creatinine and glomerular filtration rate (GFR) before and after anti-rejection treatment, steroid resistance, rejection reversal rate, graft survival were compared in two groups. The rejection reversal rate of endarteritis positive group was 90.1% (73/81), significantly higher than 77.5% (86/111) of endarteritis negative group (P = 0.022). GFR of endarteritis negative group was considerably higher before and at biopsy but significantly lower after biopsy compared with endarteritis positive group. The graft loss rate of endarteritis positive group was 17.3% (14/81) and 28.8% (32/111) of endarteritis negative group (P = 0.064). Although the graft survival since the time after kidney transplant was similar between two groups, the death-censored or death-uncensored survival since the time after anti-rejection treatment in endarteritis positive group was significantly higher than that in endarteritis negative group. Isolated endarteritis benefits the patients from better GFR and allograft survival after rejection treatment.
Selective Immunosuppression with Anti-Interleukin-2 Receptor-Targeted Therapy - Helper and Suppressor-Cell Activity in Rat Recipients of Cardiac Allografts

JW KUPIECWEGLINSKI,W PADBERG,LC UHTEG,L MA,RH LORD,D ARANEDA,TB STROM,T DIAMANTSTEIN,NL TILNEY

DOI: https://doi.org/10.1002/eji.1830170303

1987-01-01

European Journal of Immunology

Abstract:(LEW X BN)F1 cardiac allografts are rejected within 8 days in unmodified LEW rats. ART18, a mouse anti-rat IgG1 monoclonal antibody which binds specifically in vitro to the interleukin 2 receptor (IL 2R) molecule expressed primarily on activated T cells, prolongs allograft survival in a dose-dependent fashion to ca. 3 weeks (p less than 0.001) after being administered for 10 days after transplantation. This effect was related to the specificity of the antibody for IL 2R, as therapy with ART62 (a monoclonal antibody recognizing MHC class I antigen but not binding the rat IL 2R) was ineffectual. Suppressor activity was detected in spleen cells of ART18-treated grafted hosts: in vivo, splenic T suppressor/cytotoxic fraction adoptively transferred into normal LEW improved donor-specific but not third-party test graft survival (17 days, vs. 8 days, respectively, p less than 0.001); in vitro, mixed lymphocyte reaction was profoundly but nonspecifically inhibited (less than 5% of test mixed lymphocyte reaction, p less than 0.001 as compared to acutely rejecting controls). In contrast, splenic T helper (Th) cells from ART18-treated hosts were functionally depressed, as noted by their passive transfer into immunologically anergic B recipients of cardiac allografts (rejection in ca. 40 days, vs. ca. 13 days after transfer of Th from specifically sensitized rats). ART18 treatment also resulted in diminished elaboration of IL 2 as compared to normal (p less than 0.005) or acutely rejecting hosts (p less than 0.001); however, a remarkable increase in the production of IL 3 occurred (p less than 0.001). These results demonstrate that IL 2R-targeted therapy of immunocompetent graft recipients produces a selective immune defect in which donor-specific T suppressor cells are spared, but Th cells attenuated or destroyed. Decreased elaboration of IL2 concomitantly augments the release of IL 3, a lymphokine which might play a role in suppressor effect in vivo. In addition, IL 2R-targeted therapy of the immunodeficient graft recipients abrogates the capacity of alloactivated T cells to re-establish acute immune responsiveness.
[Expression of intercellular adhesion molecule-1 and vascular cell adhesion molecule in cardiac allografts and significance thereof: experiment with rats]

Xin Zhao,Guang-Min Song,Ju-Lin Xu,Xu-Jian Wang,Hui-Min Song,Xun Qu

2007-10-09

Abstract:Objective: To investigate the expression of intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) in allograft with chronic rejection (CR) after heart transplantation. Methods: Seventy-two SD rats receiving transplantation of the heats of 71 Wistar rats were divided into 4 equal groups: Group A, undergoing heterotopic cervical heart transplantation (transplanted with donor's heart subcutaneously at the neck) and receiving none intervention, and with the transplanted hearts taken out 3 d after transplantation to the end of CR; Group B, injected intravenously with the splenocytes (SPCs) of the donors on day 0, injected with cyclophomide (CP) on d2, transplanted with the donor hearts on d15, with the transplanted hearts taken out 15 - 120 days after transplantation; Group C, transplanted with the donor's heart and injected intraperitoneally with cyclosporine A (Cs A) 10 mg/kg every other day for 8 - 10 times, and with the transplanted hearts taken out 60 d after transplantation to the end of CR; and Group D, injected intravenously with the SPCs of the donors on day 0, injected with CP on d2, transplanted with the donor hearts on d15, with the transplanted hearts taken out 150 - 420 days after transplantation. Immunohistochemical method was used to detect the expression of ICAM-1 and VCAM-1 in the allografts. Results: The cardiac allograft survival time of Group B was the longest. Less ICAM-1 and VCAM-1 expression and lymphocyte infiltration were observed in SPC and CP-pretreated group. Reversely, protein expression levels of ICAM-1 and VCAM-1 were both high and significant lymphocyte infiltration was seen in Groups B and D. There was no significant difference in the expression of ICAM-1 and VCAM-1 between Groups A and C (P > 0.05). Conclusion: The expression levels of ICAM-1 and VCAM-1 are associated with the occurrence and development of rejection and have positive correlation with the severity of graft rejection. Determination of ICAM-1 and VCAM-1 can predict the function of allograft and provide evidence for early diagnosis and prevention of CR.
Poly(Lactic-Co-Glycolic Acid) (PLGA) Nanoparticles Loaded with FK506 Inhibits Acute Heart Transplantation Rejection via Regulation of Monocyte Dendritic Cells Receptor

Sheng Wang,Zhaoyun Cheng,Xianjie Chen,Guoqing Lu,Xiliang Zhu,Zhenchang Qi

DOI: https://doi.org/10.1166/jbn.2023.3551

2023-06-22

Journal of Biomedical Nanotechnology

Abstract:FK506-loaded poly(lactic-co-glycolic acid)-nanoparticles (PLGA-NPs) (PLGA-FK506-NPs) have been indicated to exert better curative effect on rejection. Therefore, were herein studied mechanism underlying PLGA-FK506-NPs suppression of heart transplantation rejection. After construction of heterotopic heart transplant model in rats and preparation of composite NPs, the animals were administered with normal saline, FK506 and PLGA-FK506-NPs. With measurement of survival time for transplanted hearts and detection of NPs toxicity, rat tissue sample was collected for Hematoxylin and eosin (H&E) staining observation. T cell infiltration and contents of IL-12 and IL-23 in dendritic cell (DCs) were also detected. In the presence of FK506 or PLGA-FK506-NPs, cell viability did not change significantly (p > 0.05), indicating low toxicity of PLGA-FK506-NPs. Importantly, treatment with FK506 or PLGA-FK506-NPs alleviated CD3+ T cell infiltration and rejection, compared with control group. Of note was that, 40% of the rat hearts in the PLGA-FK506-NPs group had an Acute Rejection (AR) level of 1R, but only 20% in the FK506 group. PLGA-FK506-NPs group had a longer heart transplant survival time than both control and FK506 groups (p <0.001). Over time, FK506 concentration decreased in blood from the rats in the FK506 and PLGA-FK506-NPs groups, indicating that, FK506 was gradually metabolized. Additionally, PLGA-FK506-NPs and FK506 resulted in increased secretion of IL-12 and IL-23, with a higher level in the PLGA-FK506-NPs group. PLGA-FK506-NPs can effectively increase FK506 content in the body, prolonging survival time of heart transplant recipients, relieving AR, and improving secretion of related factors in the mono-DCs recipients.

materials science, biomaterials,nanoscience & nanotechnology
Chelerythrine ameliorates acute cardiac allograft rejection in mice.

Qiyi Zhang,Yang Tian,Jixuan Duan,Jingjin Wu,Sheng Yan,Hui Chen,Xueqin Meng,Kwabena Gyabaah Owusu-Ansah,Shusen Zheng

DOI: https://doi.org/10.1016/j.trim.2016.07.003

IF: 2.032

2016-01-01

Transplant Immunology

Abstract:The improvement in graft survival over the past decade has been mainly due to calcineurin inhibitors, which interfere with the calcium-mediated pathway. Recently, other pathways such as those mediated by protein kinase C (PKC) are coming into view. The purpose of this study was to assess the immunosuppressive properties of chelerythrine, a specific PKC inhibitor, in preventing acute rejection in murine heterotopic heart transplantation. Mice were randomly divided into control and chelerythrine treated group. The control group received PBS while the chelerythrine treated group was given intraperitoneal injection doses (1, 5, 10mg/kg) of chelerythrine from day 0 to day 14 after heart transplantation. Six days after transplantation, cardiac allografts were harvested for further tests. The mean survival time (MST) of the cardiac allograft in untreated animals was 8days while graft MSTs observed in chelerythrine treated group was 13 and 23days at 5 and 10mg/kg treatment doses, respectively (P<0.05). Histologic assessment of the allograft in chelerythrine group showed a significant decline in histologic rejection score, as well as CD4+ and CD8+ T cell infiltration and ICAM-1+ endothelial cell activation. Down-regulation of Th1/Th2 cytokine expression was observed in chelerythrine treatment group. Meanwhile, chelerythrine was also found to inhibit the dephosphorylation of phosphorylated nuclear factor of activated T cells (NFAT) protein 1 and 4.
Long-term cardiac allograft survival across an MHC mismatch after "pruning" of alloreactive CD4 T cells

Min Hu,Debbie Watson,Geoff Y Zhang,Nicole Graf,Yuan M Wang,Mary Sartor,Brian Howden,Jeffrey Fletcher,Stephen I Alexander

DOI: https://doi.org/10.4049/jimmunol.180.10.6593

2008-05-15

Abstract:Specific tolerance to allografts has been achieved by a variety of means. We have previously shown that ex vivo removal of dividing CD4(+) T cells from an MLR or "pruning" delays skin allograft rejection. We tested pruning of alloreactive T cells as a strategy for retaining a broad T cell repertoire while removing alloreactive T cells in a model of cardiac allograft transplant. Using CFSE staining of responder BALB/c cells with stimulator C57BL/6 cells in an MLR, SCID mice were reconstituted with either dividing (D) or nondividing (ND) CD4(+) T cells derived from an MLR and then challenged with heterotopic cardiac allografts. Mice reconstituted with D CD4(+) T cells rejected cardiac allografts from the stimulator strain with a median survival time (MST) of 29 days, while mice reconstituted with ND CD4(+) T cells maintained allografts from the stimulator strain (MST of >100 days) while rejecting third-party allografts (B10.BR) (MST = 11 days). ELISPOT assays demonstrate donor-specific hyporesponsiveness of the ND CD4(+) T cells. TCR beta-chain V region (TRBV) repertoire analysis demonstrates clonal expansion within both rejecting D cardiac allografts and ND cardiac allografts surviving for the long-term. Histology showed greater allograft infiltration by the D CD4(+) T cells. The surviving ND cardiac allografts demonstrated reduced cellular infiltration and reduced incidence of allograft vasculopathy, but with the development of chronic fibrosis. Thus, pruning of alloreactive T cells allows long-term-specific cardiac allograft survival while retaining the ability to reject third-party allografts.
Use of C6-deficient rats to evaluate the mechanism of hyperacute rejection of discordant cardiac xenografts

R B Brauer,W M Baldwin 3rd,M R Daha,S K Pruitt,F Sanfilippo

1993-12-15

Abstract:C plays a critical role in the hyperacute rejection (HAR) of discordant xenografts (Xg), but the relative contribution of early vs late C components is unknown. In this study, genetic differences in C6 activity were correlated with HAR of guinea pig cardiac Xg by the rat. Seven rat strains were tested for C activity. Six strains (PVG.R1 (R1), PVG.1A (1A), DA, W/F, F344, LEW) had readily detectable C activity in the total and alternative pathways. Some PVG rats also had adequate C activity [PVG (C+)] but others [PVG (C-)] had a profound C6 deficiency. All rats with adequate C activity (n = 35) rejected cardiac Xg between 15 and 80 min. PVG (C+) (n = 6) rats also rejected cardiac Xg hyperacutely (26 +/- 12 min), whereas PVG (C-) (n = 16) rats, which had high preformed IgM natural antibody titers, rejected cardiac Xg in 1 to 2 days (2678 +/- 542 min). Transfer of serum from R1 rats to PVG (C-) recipients with vigorously beating Xg caused HAR of cardiac Xg within 116 +/- 75 min. Transfer of fresh PVG (C-) serum or heat-inactivated R1 serum did not induce HAR. HAR was characterized by intravascular platelet aggregation and interstitial hemorrhage, whereas Xg transplanted to PVG (C-) recipients had patent vessels at 30 min but were heavily infiltrated by granulocytes and monocytes at 2 days. These findings indicate that a deficiency in C6 prevents HAR but allows an accelerated acute rejection that may be mediated by the generation of vasoactive and chemotactic C3a and C5a.
Effect of PDGF-A on Cardiac Allograft Vasculopathy and Myocardial Fibrosis in Rats

ZHANG Ming-kui,WU Qing-yu,HU Jian-guo

DOI: https://doi.org/10.3760/cma.j.issn.0254-1785.2009.02.010

2009-01-01

Abstract:Objective To investigate the effect of PDGF-A on cardiac allograft vasculopathy and myocardial fibrosis in rats.Methods By using inbred Wistar rats as donors,and Sprague Dawley (SD)rats as recipients,heterotopic heart transplantation model was established,Four groups,each having 8 animals,were used.In normal heart group,Wistar rat hearts as blank control;In no rejection group,inbred Wistar rats as donors and recipients without immunosuppressive drugs,and grafts were removed on the day 60;In acute rejection group and chronic rejection group,Wistar rats as donors,SD rats as recipients,and the grafts were harvested on the day 5 without immunosuppresslve drugs in acute rejection group;In chronic rejectlon group,the graits were Immunohistochemistry was used for macrophages(CD68 positive cells)and reverse transcriptionpolymerase chain reaction(RT-PCR)assay for expression of PDGF-A mRNA in cardiac allografts.Results Macrophage infiltration was not found in normal heart group and no rejection group.In acute rejection group and chronic rejection group,macrophage infiltration was found around coronary vessels and in myocardial interstitium,especially in myocardial fibrosis area in chronic rejection allografts.The relative content of PDGF-A mRNA in normal heart group,no rejection group,acute rejection group,and chronic rejection group was 0.26±0.06,0.31±0.04,0.88±0.12,0.94±0.11respectively.PDGF-A mRNA was increased in chronic rejection group and acute rejection group significantly as compared with that in normal heart group and no rejection group(P＜0.01).Conclusion Macrophage infiltration and expression of PDGF-A are associated with cardiac allograft vasculopathy and myocardial fibrosis.
Prolongation of Survival of Fully Allogeneic Cardiac Grafts and Generation of Regulatory Cells by a Histamine Receptor 2 Antagonist

Fumihiko Inoue,Qi Zhang,Takurin Akiyoshi,Osamu Aramaki,Daiki Iwami,Kenji Matsumoto,Yuko Kitagawa,Nozomu Shirasugi,Masanori Niimi

DOI: https://doi.org/10.1097/01.tp.0000287641.69795.cc

2007-01-01

Transplantation

Abstract:Background. The effects of histamine on immunologic responses via the histamine receptor 2 (HR2) have been studied, but few investigations explored the immunomodulatory role of histamine in vivo. We examined whether the HR2 antagonist ranitidine affects the alloimmune response in a murine model of cardiac transplantation. Methods. CBA (H-2k) recipients were given no treatment or one intravenous injection of ranitidine on the day of transplantation of a heart from C57BL/10 (H-2b) donors. Survival of the allografts was recorded. The effect of the ranitidine treatment on cell proliferation and cytokine production was assessed by mixed leukocyte culture and enzyme-linked immunosorbent assays. An adoptive transfer study was conducted to determine whether regulatory cells were generated. The effect on graft survival of adding FK506 to the ranitidine treatment was also examined. Results. CBA recipients given ranitidine (60 mg/kg) had prolonged graft survival (median survival time [MST], 87 days). Ranitidine treatment also suppressed the proliferation of splenocytes and production of interleukin (IL)-2 and up-regulated IL-10 production. Adoptive transfer of splenocytes and CD4+ cells from ranitidine-treated allograft recipients induced significant prolongation of allograft survival in naive secondary recipients (MST, 71 and >100 days, respectively). CBA recipients given both ranitidine and FK506 (0.1 mg/kg/day for 14 days) had indefinite survival of cardiac allografts (MST, >100 days). CBA recipients treated with FK506 alone rejected the allografts (MST, 27 days). Conclusion. In our model, ranitidine treatment induced significantly prolonged survival of fully allogeneic cardiac grafts, generated CD4+ regulatory cells, and indefinite survival when combined with FK506 (0.1 mg/kg/day).
Attenuation of Rat Chronic Small Bowel Allograft Rejection by N‐3 Polyunsaturated Fatty Acids is Associated with Reduced Expression of Graft IL‐15

Jian Wang,Yousheng Li,Jieshou Li

DOI: https://doi.org/10.1111/petr.12120

2013-01-01

Pediatric Transplantation

Abstract:Interleukin‐15 was found to play key roles in various immunological processes including chronic rejection after renal and cardiac transplantation. n‐3 polyunsaturated fatty acids (n‐3 PUFA) have shown beneficial effects to chronic allograft rejection. The objective of this study is to search the possible mechanism of this inhibitory effect in chronic small bowel allograft rejection. Animals were divided into three groups: isograft (CsA + corn oil‐supplemented diet); allograft (CsA + corn oil‐supplemented diet); and allograft (CsA + fish oil‐supplemented diet). Donor intestines from F344 rats were transplanted orthotopically into Lewis rat recipients. CsA was administered at 5 mg/kg/day for 2 wk post‐operatively. Post‐transplant weight was recorded. Histopathological changes and graft IL‐15 expression were measured on POD 90. Chronic small bowel allograft rejection developed on POD 90. n‐3 PUFA significantly decreased the score of chronic rejection and increased the post‐operative weight gain rate. This attenuation is associated with reduced graft IL‐15 expression. n‐3 PUFA contributed to improved pathological and clinical outcome during chronic small bowel allograft rejection, and this improvement was associated with reduced graft IL‐15 expression.

Autofluorescence imaging colonoscopy for the diagnosis of dysplasia in ulcerative colitis.

Efficacy of Ctla4-Ig in Preventing Acute Rejection of Fully Allogeneic Heart Allografts in Sensitized Recipients

Precise Treatment of Acute Antibody-Mediated Cardiac Allograft Rejection in Rats Using C4d-targeted Microbubbles Loaded with Nitric Oxide

A novel approach for HPLC determination of 2-cynaoacetamide using derivatization procedure with 2-hydroxyacetophenone as a new useful derivatization reagent.

Combination of cyclosporine A with donor bone marrow cell infusion prolongs heterotopic rat cardiac allograft survival time

Synergistic Effect of CsA and DBMC on Heterotopic Rat Cardiac Allograft Survival

Impact of Acute Rejection Episodes on Long-Term Renal Allograft Survival

Effect of acute humoral rejection on renal allograft survival

Effect of β-Nicotinamide Adenine Dinucleotide on Acute Allograft Rejection After Rat Lung Transplantation

[Completely Reversed Acute Rejection Episodes Do Not Influence the Long-Term Renal Allograft Survival].

Inactivation Of T-Cell Receptor-Mediated Integrin Activation Prolongs Allograft Survival In Amap-Deficient Mice

Histological Isolated Endarteritis Benefits Glomerular Filtration Rate And Allograft Survival After Anti-Rejection Treatment

Selective Immunosuppression with Anti-Interleukin-2 Receptor-Targeted Therapy - Helper and Suppressor-Cell Activity in Rat Recipients of Cardiac Allografts

[Expression of intercellular adhesion molecule-1 and vascular cell adhesion molecule in cardiac allografts and significance thereof: experiment with rats]

Poly(Lactic-Co-Glycolic Acid) (PLGA) Nanoparticles Loaded with FK506 Inhibits Acute Heart Transplantation Rejection via Regulation of Monocyte Dendritic Cells Receptor

Chelerythrine ameliorates acute cardiac allograft rejection in mice.

Long-term cardiac allograft survival across an MHC mismatch after "pruning" of alloreactive CD4 T cells

Use of C6-deficient rats to evaluate the mechanism of hyperacute rejection of discordant cardiac xenografts

Effect of PDGF-A on Cardiac Allograft Vasculopathy and Myocardial Fibrosis in Rats

Prolongation of Survival of Fully Allogeneic Cardiac Grafts and Generation of Regulatory Cells by a Histamine Receptor 2 Antagonist

Attenuation of Rat Chronic Small Bowel Allograft Rejection by N‐3 Polyunsaturated Fatty Acids is Associated with Reduced Expression of Graft IL‐15